A critical evaluation of the Braak staging scheme for Parkinson's disease.
Braak and colleagues have proposed that, within the central nervous system, Parkinson's disease (PD) begins as a synucleinopathy in nondopaminergic structures of the lower brainstem or in the olfactory bulb. The brainstem synucleinopathy is postulated to progress rostrally to affect the substantia nigra and cause parkinsonism at a later stage of the disease. In the context of a diagnosis of PD, made from current clinical criteria, the pattern of lower brainstem involvement accompanying mesencephalic synucleinopathy is often observed. However, outside of that context, the patterns of synucleinopathy that Braak described are often not observed, particularly in dementia with Lewy bodies and when synucleinopathy occurs in the absence of neurological manifestations. The concept that lower brainstem synucleinopathy represents "early PD" rests on the supposition that it has a substantial likelihood of progressing within the human lifetime to involve the mesencephalon, and thereby cause the substantia nigra pathology and clinical parkinsonism that have heretofore defined the disease. However, the predictive validity of this concept is doubtful, based on numerous observations made in populations of aged individuals who, despite the absence of neurological signs, have brain synucleinopathy ranging up to Braak stages 4 to 6 at postmortem. Furthermore, there is no relation between Braak stage and the clinical severity of PD. We conclude that the relation between patterns of abnormal synuclein immunostaining in the human brain and the disease entity now recognized as PD remains to be determined.
Burke
Robert E
RE
Department of Neurology, Columbia University Medical Center, New York, NY, USA. rb43@columbia.edu
Dauer
William T
WT
Vonsattel
Jean Paul G
JP
D015415:Biomarkers / Q000032:analysis; D001921:Brain / Q000473:pathology*; D018450:Disease Progression; D042241:Early Diagnosis; D006801:Humans; D007150:Immunohistochemistry / Q000592:standards; D016631:Lewy Bodies / Q000473:pathology*; D010300:Parkinson Disease / Q000473:pathology*; D011237:Predictive Value of Tests; D011379:Prognosis; D012249:Rhombencephalon / Q000473:pathology; D012720:Severity of Illness Index; D051844:alpha-Synuclein / Q000032:analysis*
D015415:Biomarkers; D051844:alpha-Synuclein